Ichor Holdings (ICHR) Q2 2026 Earnings Call Transcript

Ichor reported Q2 net sales of $294.8M (+15% sequentially, +24% YoY) and non-GAAP EPS of $0.34 (3-year record), with non-GAAP gross margin of 14.1% (up 130bps sequentially and above the high end of guidance). Management raised Q3 revenue guidance to $315M–$345M (midpoint implies +12% sequential growth) and non-GAAP EPS to $0.40–$0.50, while targeting another +100bps/quarter gross margin expansion through the rest of 2026. The company completed a $200M ATM equity offering (net proceeds ~$195.4M), lifting cash to $256M, and guided 2H revenue to be at least 25% higher than 1H with demand visibility extending into 2027 despite isolated end-of-quarter supply constraints.

Analysis

The key signal is that ICHR is beginning to look less like a pure cyclical supplier and more like a margin expansion story driven by internalization. If management is right, the next leg is not just revenue growth from AI capex, but a higher-quality revenue mix with more proprietary content and less dependence on third-party bottlenecks, which should compress working-capital volatility and lift through-cycle EBITDA.

Near term, the stock likely trades on whether the promised sequence of margin gains shows up before the market gets bored of the AI/WFE narrative. The ATM raise is helpful for liquidity but also increases scrutiny on cash conversion: if inventory keeps building faster than revenue, investors may start discounting the quality of growth even if reported margins improve. The flow-control/supply-chain comments matter because they imply the current beat is still partly timing-related; if lead times normalize faster than internal capacity ramps, the step-up can reverse in one or two quarters.

The contrarian view is that consensus may be overpricing 2027 visibility and underpricing the digestion risk between now and then. ICHR can rerate if gross margin keeps expanding and internal content continues to rise, but the setup is vulnerable to any pause in WFE orders, customer inventory correction, or a plateau in margin improvement before the Malaysia ramp fully monetizes. Best-risk/reward is to own the idiosyncratic execution story against sector beta, not as a standalone momentum trade.

Key Decisions for Investors

• Long ICHR vs. short SOXX for 1-3 months to isolate company-specific margin expansion from broader semi-cycle beta; thesis breaks if ICHR guide stops implying >10% sequential growth or gross margin fails to improve by at least ~50 bps next quarter.
• Accumulate ICHR on any post-earnings pullback for a 6-12 month hold; this is a balance-sheet-backed structural story, but only if cash conversion begins to normalize by 1H27 and inventory does not outrun sales for another two quarters.
• If already long the stock, trim into strength rather than chase immediate upside; the ATM dilution and working-capital drag make the risk/reward less attractive after a sharp gap-up than on a fade toward the pre-call trend line.
• Set a hard watch item on operating cash flow and inventory turns into the next two prints; if turns do not improve by early 2027, treat the margin-expansion thesis as stalled and exit the position.